HUGE

FSD Pharma Inc.

1.07 USD

Last updated Dec 3, 10:34 UTC

Yesterday HIGH

$1.1

Yesterday LOW

$1.01

52w HIGH

$2.1

52w LOW

$0.62

EPS

-0.03

PE

-35.67

Next Earnings

Apr 1, 2024

Overview News Government Trades

FSD Pharma Inc. stock is down 0% since 30 days ago. The next earnings date is Apr 1, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 16.67% of the previous 5 December’s closed higher than November.

FSD Pharma Inc. operates as a pharmaceutical research and development company. Its lead candidate includes FSD-201 that is in the Phase II clinical trial to treat COVID-19 disease. The company also focuses on Lucid-PSYCH, a psychoactive molecule identified for the potential treatment of neuropsychiatric disorders.

Stock Exchange

NASDAQ

Sector

Manufacturing

Industry

Pharmaceutical Products

Headquarters

-

Website

fsdpharma.com

Lara Goldstein

Thu Aug 3, 2023

Psyched: Portugal Decriminalizes Synthetic Drugs, Anorexia And Psilocybin, LSD Microdosing, California & More

A Revolutionary Approach: Portugal Decriminalizes Synthetic Drugs Portugal’s Parliament recently decriminalized the use of synthetic drugs. The new law equates the legal treatment of these substances with that of classic drugs.
Happy Mohamed

Wed Aug 2, 2023

FSD Pharma Signs Definitive Agreement To Launch UNBUZZD, A Revolutionary Rapid Alcohol Detoxification Drink

Launch in the Consumer Market to be Led by Former Executives from Coca-Cola and Celsius Holdings TORONTO, ON / ACCESSWIRE / August 2, 2023 / FSD Pharma Inc. (NASDAQ:HUGE)(CSE:HUGE)(FRA:0K9A) ("FSD Pharma"
Lara Goldstein

Fri Jul 28, 2023

Small Pharma's Q1 2024: Revamping Strategy And Potential Fast-Tracked Clinical Trial

UK’s short-acting psychedelics developer Small Pharma (OTCQB: DMTTF) published its financial results for the fiscal first quarter ended May 31, 2023:
Benzinga Newsdesk

Mon Jul 17, 2023

FSD Pharma Says Arbitration Panel Finds That Syneos Health Failed To Use Commercially Reasonable Efforts In Conducting Trial For FSD 201
Lara Goldstein

Tue Jul 4, 2023

Psyched: A $100M Donation Pledge, Frank Biden Gets Candid, New Search Trends & More

World's Largest Psychedelics Conference Boasts 12K Attendees
Lara Goldstein

Tue Jun 20, 2023

FSD Pharma Announces Agreement To Grant Exclusive Rights To Recreational Alcohol Misuse Technology
Lara Goldstein

Mon May 15, 2023

Psyched: $20M Research Fund, LSD Microdosing For Cancer, MEAI Enters Clinical Stage, Reform Update & More

Researchers At Johns Hopkins Get $20M Fund Prompted By Longtime Psychedelics Scientist Johns Hopkins University academics received a boost in funding thanks to the recently launched Roland R. Griffiths Ph.D. Professorship Fund.
Lara Goldstein

Wed May 10, 2023

Promising Multiple Sclerosis Drug Candidate Advances: First Clinical Trial Dosing Completed

FSD Pharma Inc. (NASDAQ: HUGE), a biopharma company developing innovative assets and biotech solutions for the treatment of neurodegenerative, inflammatory and metabolic disorders, announced the first cohort of participants on its
Lara Goldstein

Mon May 8, 2023

Psyched: Psychedelics Reimbursement, Amanita Muscaria Boom, $53M Material Breach Lawsuit & More

EXCLUSIVE: AMA Moves Toward Psychedelic Therapy Reimbursement, Filing A Gap In Regulations
Maureen Meehan

Fri May 5, 2023

Lawsuit: GBB Drink Lab Seeks $53M From FSD Pharma For Nondisclosure Contract Breach & Trade Secret Misappropriation

GBB Drink Lab, which makes the world’s first formulated drink that aids in rapid blood alcohol detoxification - a handy tool, has filed a lawsuit against the psychedelics biotech company FSD Pharma (NASDAQ: HUGE).